rs12487736 — SCAP SCAP Val798Ile

SCAP Val798Ile — The Cholesterol-Sensor Variant at the Heart of Plaque Formation

Before a cell can respond to low cholesterol by making more, it needs to sense the deficit. That sensing job belongs to SCAP (SREBP cleavage-activating protein)¹¹ SCAP (SREBP cleavage-activating protein)
a seven-transmembrane sterol-sensing protein in the ER membrane that escorts SREBP transcription factors to the Golgi for proteolytic activation. When cholesterol is plentiful, SCAP is detained at the ER by INSIG proteins. When cholesterol drops, SCAP escorts SREBP-2 to the Golgi, where it is cleaved and activated — driving LDL receptor and HMG-CoA reductase expression to restore cholesterol supply. The rs12487736 variant changes valine to isoleucine at position 798 of SCAP, sitting within the WD-repeat domain that contacts SREBP-2. This amino acid substitution may subtly alter SCAP's interaction geometry with SREBP-2 and its response to cholesterol feedback signals.

The Mechanism

The SCAP Val798Ile substitution lies in the carboxy-terminal WD40 repeat region of SCAP, which mediates direct protein-protein contact with SREBP-2's regulatory domain. The functional consequence of this change is not yet fully characterized at the structural level, but population and clinical data suggest it shifts the SCAP–INSIG–SREBP-2 axis toward a state that promotes vascular cholesterol accumulation. In genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples²² genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples
Fan et al., Thrombosis Journal, 2008, SREBF-2 mRNA was significantly downregulated in carotid plaques (p=0.02), suggesting that reduced SREBF-2 transcriptional activity in inflamed vascular tissue — potentially exacerbated by SCAP functional variants — is a feature of established atherosclerosis rather than a compensatory response.

Under inflammatory conditions, the mTOR pathway activates the SCAP–SREBP-2 complex, increasing its translocation from the ER to the Golgi and driving excess LDL receptor expression and cholesterol uptake into vascular cells. SCAP knockdown in smooth muscle cells of ApoE-/- mice³³ SCAP knockdown in smooth muscle cells of ApoE-/- mice
Li et al., FASEB J, 2019 significantly reduced atherosclerotic plaque burden, confirming SCAP as a causal driver of lesion formation rather than merely a correlate. The rs12487736 variant, by modulating SCAP's functional state, may tilt this balance toward greater lipid accumulation in susceptible individuals — especially when co-inherited with functional variants in the SREBF2 gene itself.

The Evidence

The most compelling cardiovascular evidence comes from an autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease⁴⁴ autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease
Fan et al., Thromb J, 2008. Researchers genotyped SCAP 2386A>G (rs12487736) and SREBF2 1784G>C (rs2228314) and correlated genotypes with coronary artery narrowing and lesion characteristics. On its own, the SCAP G allele (plus-strand C at rs12487736) did not reach independent significance for SCD risk. However, men carrying both the SCAP G allele and the SREBF2 C allele had a 2.68-fold elevated risk of sudden cardiac death (OR 2.68, 95% CI 1.07–6.71; interaction p=0.046), pointing to a gene-gene amplification effect when both components of the SCAP–SREBP-2 circuit carry functional variants simultaneously.

Population-level data reinforce the pathway's relevance. A case-control study in 1,801 Han Chinese adults⁵⁵ A case-control study in 1,801 Han Chinese adults
Liu et al., Atherosclerosis, 2010 found three-locus interactions among SREBP2, SCAP, and INSIG1/2 variants significantly predicting coronary heart disease risk (p≤0.001). In pediatric cohorts, the variant also influences metabolic phenotypes: in 2,021 Chinese schoolchildren⁶⁶ 2,021 Chinese schoolchildren
Yang et al., PLoS One, 2017, rs12487736 was associated with both systolic BP (β=1.66, p=0.003) and diastolic BP (β=1.35, p=0.024), with a 36% elevated odds of high blood pressure in overweight/obese children carrying the risk allele (OR 1.36, 95% CI 1.02–1.82). The same variant interacts with dietary patterns to modulate blood pressure response, suggesting its effects are amplified under metabolic stress conditions.

A study of 614 HIV-positive individuals on antiretroviral therapy⁷⁷ study of 614 HIV-positive individuals on antiretroviral therapy
Lazzaretti et al., ScientificWorldJournal, 2013 also found the variant significantly associated with HDL-cholesterol levels, consistent with SCAP's broad role in sterol balance across lipoprotein fractions.

Practical Actions

For CC homozygotes, the most actionable implication is the additive risk when combined with the SREBF2 C allele (rs2228314). Checking both variants together informs a meaningful risk stratification that neither variant achieves alone. The variant's effect on LDL receptor regulation makes it relevant to statin pharmacology: SCAP-mediated SREBP-2 activation is a key mechanism by which statins amplify LDLR transcription. Variants that blunt this relay may partially attenuate the LDL-lowering response to standard statin doses, though direct pharmacogenomic evidence for this specific variant remains sparse.

For individuals with overweight or obesity, this variant's interaction with metabolic burden on blood pressure is an additional reason to track both blood pressure and lipid levels systematically, as the variant appears to act as a conditional risk amplifier in the context of metabolic stress.

Interactions

The critical interaction is with SREBF2 rs2228314 (Gly595Ala). SCAP is the direct chaperone and sterol sensor for SREBP-2. When both SCAP (Val798Ile, rs12487736) and SREBP-2 (Gly595Ala, rs2228314) carry functional variants, the entire cholesterol-sensing circuit is doubly compromised — the sensor that detects cholesterol (SCAP) and the transcription factor it activates (SREBP-2) both function suboptimally. The 2.68-fold SCD risk in Finnish men demonstrates that this co-inheritance is clinically significant.

INSIG1 and INSIG2 variants at the same pathway node also interact with SCAP variants in determining coronary heart disease risk in Chinese cohorts — the INSIG–SCAP–SREBP axis behaves as an integrated cholesterol sensing unit whose aggregate genetic load matters more than any single variant.